UPDATE to CDER COVID19 Webpages

The Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) is engaged in numerous activities to protect and promote public health during the COVID-19 pandemic, ranging from the acceleration of development for treatments for COVID-19, maintaining and securing drug supply chains, providing guidance to manufacturers, advising developers on how to handle clinical trial issues, and keeping the public informed. Getting timely information to those who need it is among CDER’s highest priorities during this pandemic. Recently CDER has created a number of COVID-19 related webpages, and edited others, to highlight appropriate points of contact within CDER on topics such as clinical trials, drug shortages, hand sanitizers, compounding, and other areas. Each of these areas has an associated email address so that inquiries will go immediately to the correct point of contact within CDER.    Please visit Coronavirus (COVID-19) | Drugs for direct access to webpages, and contact information on, the topics mentioned above. CDER will update these webpages as necessary.

Visit Coronavirus (COVID-19) | Drugs